Support SB346:

Give Ohio the Exemptions Voted for in Issue 5 - Return Freedom of Choice & Let Free Market Drive the Decisions of Business Owners
Home
About Us
Editorial
Contact Us
Anti Smoking Groups
Growing Resistance
Legal
Legislators Support SB346
LIES
Lobbying Influence
News-IMPORTANT
Non-Profits: Anything BUT
Ohio Losses
Politics and Bans
Tobacco Control: BUSTED!
TRUTH
Built on LIES
Constitutional Impact
Damage to Businesses
McFadden
Who REALLY profits financially?
Studies
Studies Comparison
What can we do?
Site Map
"Studies" Comparison
Studies is a loose term. These "studies" are meta analyses.  
The link below is an excellent source for understanding the jargon used in thses "studies".  It explains what RR (Relative Risk) is, OR (Odds Ration), CI (Confidence Interval) and the statistical significance.
 
This source compares all know studies up to 2006. http://www.data-yard.net/ets_summary/study_list.htm  
 
IMPORTANT!!  Their reasoning proves these studies are junk.
 
National Cancer Institute - "In epidemiologic research, relative risks of less than 2 are considered small and usually difficult to interpret.  Such increases may be due to chance, statistical bias or effects of confounding factors that are sometimes not evident". From "Abortion & possible risk for breast cancer: analysis and inconsistencies" october 26, 1994
 
Word Health Organization/International Agency for Research on Cancer - "Relative risks of less than 2.0 may readily reflect some unperceived bias or confounding factor, those over 5.0 are unlikely to do so." - from Breslow and Day, 1980, Statistical methods in cancer research, Vol1, The analysis of case control studies, Published by the WHO, IARC, Sci. Pub. No 32, Lyon, p. 36
 
Sir Richard Doll - "...when relative risk lies between 1 and 2...problems of interpretation may become acute and it may be extremely difficult to disentangle the various contributions of biased information, confounding of two or more factors and cause and effect."  From "The Causes of Cancer" by Richard Doll, F.R.S. and Richard Peto.  Oxford-New York, Oxford University Press.  1981, p. 1219
 
FDA - "Relative risks of 2 have a history of unreliability" - Robert Temple, director of drug evaluation at the Food and Drug Administration
 
FDA - "My basic rule is if the relative risk isn't at least 3 or 4, forget it." - Robert Temple, director of drug evaluation at the Food and Drug Administration
 
*Average cancer risk elevation for exposure to passive smoke: about 20% (Relative Risk = 1.2)
Average cardiovascular disease risk elevation for exposure to passive smoke: above 30% (Relative Risk = 1.3)
 
THEY PROVE THE CASE FOR US.
 
 
What an epidemiological study MUST warrant:
 
The long list of errors
According to Forces:
 
  1. The claims of exposure are not authentic.  Exposure is not measured.  The studies actually measure nothing but rely on the vague and grossly imprecise recall of queried subjects who attempt to evoke in a few minutes their individual lifetime memories of passive smoking exposure.
  2. Errors in individual exposure recollection, most likely large, are unknown, and are unknowable.  Digitized numerical claims of exposure are, therefore, incongruous and impermissible.  Their numerical representation give an impression of reliability and precision that is demonstrably false and misleading.
  3. A recall bias has been demonstrated to be larger in subjects who are more likely to amplify their recall of passive smoking exposure as a justification for their disease, with lung cancer or cardio vascular disease. (remember when you or your wife was pregnant-remember seeing all the pregnant women you never noticed before?)
  4. A misclassification bias has been demonstrated to be larger in subjects with lung cancer or cardio vascular disease because they are more likely than healthy subjects to classify themselves as non smokers.
  5. A mismatch error of cases and controls is inevitable because the groups compared are not homogeneous and differ in many characteristics other than recall of passive smoking exposure.
  6. Confounding errors by definition are likely to be more prevalent among lung cancer and cardio vascular disease cases.  Confounders are all other known and unknown potential causes of lung cancer and cardio vascular disease that interfere with the specific attribution of risk to passive smoking.
  7. Probable errors of disease diagnosis are seldom addressed by passive smoking studies.
  8. Publication errors have been found to favor the publication of studies that claim associations of increased risk.
  9. Statistical errors of sampling and statistical significance are grossly inconsistent among passive smoking studies owing to the feeble differentials of exposure recall and the small number of subjects in each study.  A majority of studies have not reached statistical significance.  In any event, significant or not, the statistical indices of all passive smoking studies are illusory because they are derived from the grossly illusory and misleading numerical renderings of vague individual exposure recalls.
  10.  Results from different studies have not ben consistent and reproducible.
  11.  Epidemologic criteria of causal inference are not met by passive smoking studies.
 
Attempts to summarize the results of different studies by meta-analysis statistical techniques are illegitimate.  Results are obtained by pooling heterogeneous and selected studies, giving arbitrary preferential weights to certain studies, which, in any case, are handicapped by the sources of error listed above.